Anavex Life Sciences (AVXL) Total Current Liabilities (2012 - 2022)

Anavex Life Sciences has reported Total Current Liabilities for 11 years, with the latest figure at $9.5 million in Q2 2022.

• Quarterly Total Current Liabilities changed N/A year-over-year to $9.5 million in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $9.5 million (changed N/A YoY) and the FY2021 annual result came in at $10.8 million, up 47.81% from the prior year.
• Total Current Liabilities advanced to $9.5 million in Q2 2022 per AVXL's latest filing, from $8.1 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $10.8 million in Q3 2021 and troughed at $3.2 million in Q2 2018.
• A 5-year average of $6.6 million and a median of $6.4 million in 2019 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2018 and 2020: Total Current Liabilities surged 120.62% in 2018, then dropped 2.23% in 2020.
• Over 5 years, Total Current Liabilities stood at $4.9 million in 2018, then rose by 12.06% to $5.5 million in 2019, then soared by 47.03% to $8.0 million in 2020, then surged by 31.06% to $10.5 million in 2021, then dropped by 9.92% to $9.5 million in 2022.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $9.5 million, $8.1 million, and $10.5 million for Q2 2022, Q1 2022, and Q4 2021 respectively.